Serum free light chains and multiple myeloma: Is it time to extend their application?

Serum free light chains and multiple myeloma: Is it time to extend their application?

Abstract In nonsecretory, oligo‐secretory, and light chain multiple myeloma patients, serial sFLC evaluation could precede biochemical and clinical disease progression, even in extramedullary relapse, thus initiating early treatment with novel anti‐MM agents.

Bibliographic Details
Main Authors: Uros Markovic, Valerio Leotta, Daniele Tibullo, Rachele Giubbolini, Alessandra Romano, Vittorio Del Fabro, Nunziatina Laura Parrinello, Maria Teresa Cannizzaro, Francesco Di Raimondo, Concetta Conticello
Format: Article
Language:English
Published: Wiley 2020-04-01
Series:Clinical Case Reports
Subjects:
disease progression
extramedullary relapse
multiple myeloma
serological markers
serum free light chains
Online Access:https://doi.org/10.1002/ccr3.2636
Description
Summary:Abstract In nonsecretory, oligo‐secretory, and light chain multiple myeloma patients, serial sFLC evaluation could precede biochemical and clinical disease progression, even in extramedullary relapse, thus initiating early treatment with novel anti‐MM agents.
ISSN:2050-0904

Similar Items